{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:22:53Z","timestamp":1793316173276,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000926","name":"Wallace Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41386-022-01344-y","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T01:02:45Z","timestamp":1654218165000},"page":"1854-1862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder"],"prefix":"10.1038","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1462","authenticated-orcid":false,"given":"Deepak Cyril","family":"D\u2019Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shariful A.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Taylor","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamideh","family":"Safi-Aghdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas V.","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohini","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"1344_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"1344_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181\u201397.","journal-title":"J Psychopharmacol"},{"key":"1344_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","volume":"18","author":"EA Schindler","year":"2021","unstructured":"Schindler EA, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, et al. Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics. 2021;18:534\u201343.","journal-title":"Neurotherapeutics."},{"key":"1344_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/00952990.2016.1200060","volume":"43","author":"MP Bogenschutz","year":"2017","unstructured":"Bogenschutz MP. It\u2019s time to take psilocybin seriously as a possible treatment for substance use disorders. Am J Drug Alcohol Abus. 2017;43:4\u20136.","journal-title":"Am J Drug Alcohol Abus"},{"key":"1344_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28:983\u201392.","journal-title":"J Psychopharmacol"},{"key":"1344_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cpt.557","volume":"101","author":"DE Nichols","year":"2017","unstructured":"Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Therapeutics. 2017;101:209\u201319.","journal-title":"Clin Pharmacol Therapeutics"},{"key":"1344_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78:481\u20139.","journal-title":"JAMA Psychiatry"},{"key":"1344_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/BF02157378","volume":"12","author":"S SzARA","year":"1956","unstructured":"SzARA S. Dimethyltryptamin: its metabolism in man; the relation of its psychotic effect to the serotonin metabolism. Experientia. 1956;12:441\u20132.","journal-title":"Experientia."},{"key":"1344_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/BF00367455","volume":"223","author":"A Dittrich","year":"1976","unstructured":"Dittrich A, Bickel P, Schopf J, Zimmer D. [Comparison of altered states of consciousness induced by the hallucinogens (\u2013)-delta9-trans-tetrahydrocannabinol (delta9-THC) and N,N-dimethyltryptamine (DMT) (author\u2019s transl)]. Arch Psychiatr Nervenkr. 1976;223:77\u201387.","journal-title":"Arch Psychiatr Nervenkr"},{"key":"1344_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1055\/s-2005-916185","volume":"38","author":"E Gouzoulis-Mayfrank","year":"2005","unstructured":"Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, et al. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry. 2005;38:301\u201311.","journal-title":"Pharmacopsychiatry."},{"key":"1344_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994;51:98\u2013108.","journal-title":"Arch Gen Psychiatry"},{"key":"1344_CR12","doi-asserted-by":"crossref","unstructured":"Strassman RJ. Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res. 1996;73:121\u20134.","DOI":"10.1016\/0166-4328(96)00081-2"},{"key":"1344_CR13","first-page":"201","volume":"9","author":"S Sz\u00e1ra","year":"2007","unstructured":"Sz\u00e1ra S. DMT at fifty. Neuropsychopharmacol Hung. 2007;9:201\u20135.","journal-title":"Neuropsychopharmacol Hung"},{"key":"1344_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-51974-4","volume":"9","author":"C Timmermann","year":"2019","unstructured":"Timmermann C, Roseman L, Schartner M, Milliere R, Williams LT, Erritzoe D, et al. Neural correlates of the DMT experience assessed with multivariate EEG. Sci Rep. 2019;9:1\u201313.","journal-title":"Sci Rep"},{"key":"1344_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature08506","volume":"462","author":"MJ Keiser","year":"2009","unstructured":"Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462:175\u201381.","journal-title":"Nature."},{"key":"1344_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/annotation\/e580a864-cf13-40c2-9bd9-b9687a6f0fe4","volume":"5","author":"TS Ray","year":"2010","unstructured":"Ray TS. Psychedelics and the human receptorome. PLoS One. 2010;5:1\u201317.","journal-title":"PLoS One."},{"key":"1344_CR17","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1126\/science.1166127","volume":"323","author":"D Fontanilla","year":"2009","unstructured":"Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009;323:934\u20137.","journal-title":"Science."},{"key":"1344_CR18","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00702-009-0308-8","volume":"116","author":"NV Cozzi","year":"2009","unstructured":"Cozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shulgin AT, Daley PF, et al. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J Neural Transm. 2009;116:1591\u20139.","journal-title":"J Neural Transm"},{"key":"1344_CR19","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1124\/mol.60.6.1181","volume":"60","author":"JR Bunzow","year":"2001","unstructured":"Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharm. 2001;60:1181\u201388.","journal-title":"Mol Pharm"},{"key":"1344_CR20","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1126\/science.175.4028.1365","volume":"175","author":"JM Saavedra","year":"1972","unstructured":"Saavedra JM, Axelrod J. Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro. Science. 1972;175:1365\u20136.","journal-title":"Science."},{"key":"1344_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","volume":"37","author":"FdL Os\u00f3rio","year":"2015","unstructured":"Os\u00f3rio FdL, Sanches RF, Macedo LR, Dos Santos RG, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Braz J Psychiatry. 2015;37:13\u201320.","journal-title":"Braz J Psychiatry"},{"key":"1344_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological Med. 2019;49:655\u201363.","journal-title":"Psychological Med"},{"key":"1344_CR23","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/ph13110334","volume":"13","author":"AM Brito-da-Costa","year":"2020","unstructured":"Brito-da-Costa AM, Dias-da-Silva D, Gomes NG, Dinis-Oliveira RJ, Madureira-Carvalho \u00c1. Toxicokinetics and toxicodynamics of ayahuasca alkaloids N, N-dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine: clinical and forensic impact. Pharmaceuticals. 2020;13:334.","journal-title":"Pharmaceuticals."},{"key":"1344_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/da.22968","volume":"37","author":"BN Gaynes","year":"2020","unstructured":"Gaynes BN, Lux L, Gartlehner G, Asher G, Forman\u2010Hoffman V, Green J, et al. Defining treatment\u2010resistant depression. Depression Anxiety. 2020;37:134\u201345.","journal-title":"Depression Anxiety"},{"key":"1344_CR25","doi-asserted-by":"crossref","unstructured":"Cozzi NV, Daley PF. Synthesis and characterization of high-purity N,N-dimethyltryptamine (DMT) hemifumarate for human clinical trials. Drug Test Anal. 2020;12:1483\u201393.","DOI":"10.1002\/dta.2889"},{"key":"1344_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0166-4328(96)00081-2","volume":"73","author":"RJ Strassman","year":"1995","unstructured":"Strassman RJ. Human psychopharmacology of N, N-dimethyltryptamine. Behav Brain Res. 1995;73:121\u20134.","journal-title":"Behav Brain Res"},{"key":"1344_CR27","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.clinthera.2018.04.003","volume":"40","author":"RI Shader","year":"2018","unstructured":"Shader RI. Safety versus tolerability. Clin Therapeutics. 2018;40:672\u20133.","journal-title":"Clin Therapeutics"},{"key":"1344_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.schres.2008.02.020","volume":"103","author":"OJ Mason","year":"2008","unstructured":"Mason OJ, Morgan CJ, Stefanovic A, Curran HV. The Psychotomimetic States Inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophrenia Res. 2008;103:138\u201342.","journal-title":"Schizophrenia Res"},{"key":"1344_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/YIC.0b013e3282f948f5","volume":"23","author":"JB Williams","year":"2008","unstructured":"Williams JB, Kobak KA, Bech P, Engelhardt N, Evans K, Lipsitz J, et al. The GRID-HAMD: standardization of the Hamilton depression rating scale. Int Clin Psychopharmacol. 2008;23:120\u20139.","journal-title":"Int Clin Psychopharmacol"},{"key":"1344_CR30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc: Ser B (Methodol). 1995;57:289\u2013300.","journal-title":"J R Stat Soc: Ser B (Methodol)"},{"key":"1344_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619\u201327.","journal-title":"Lancet Psychiatry"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01344-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01344-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01344-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T06:45:42Z","timestamp":1727333142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01344-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1344"],"URL":"https:\/\/doi.org\/10.1038\/s41386-022-01344-y","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"29 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}